Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
J Am Acad Dermatol
; 70(2): 223.e1-17; quiz 240-2, 2014 Feb.
Article
em En
| MEDLINE
| ID: mdl-24438970
Palavras-chave
BSA; CR; CRR; CTCL; ECP; EORTC; European Organization of Research and Treatment of Cancer; HDACi; IFNα; ISCL; International Society for Cutaneous Lymphoma; MF; NBUVB; NCCN; NK; NM; NMSC; National Comprehensive Cancer Network; ORR; PUVA; RAR; RXR; SS; Sézary syndrome; TNMB; TSEBT; USCLC; UVB; United States Cutaneous Lymphoma Consortium; body surface area; complete response; complete response rate; cutaneous T-cell lymphoma; extracorporeal photopheresis; histone deacetylase inhibitor; immunomodulators; interferon-alfa; mSWAT; modified severity-weighted assessment tool; mycosis fungoides; narrowband ultraviolet B light; natural killer; nitrogen mustard; nonmelanoma skin cancer; overall response rate; phototherapy; prognosis; psoralen plus ultraviolet A light phototherapy; retinoic acid receptor; retinoid X receptor; skin-directed treatment; staging; systemic treatment; targeted therapies; topical nitrogen mustard; topical retinoids/rexinoids; topical corticosteroids; total skin electron beam therapy; tumor, node, metastasis, blood; ultraviolet B light
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fototerapia
/
Neoplasias Cutâneas
/
Linfoma Cutâneo de Células T
/
Micose Fungoide
/
Fotoferese
/
Fatores Imunológicos
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
Idioma:
En
Revista:
J Am Acad Dermatol
Ano de publicação:
2014
Tipo de documento:
Article